Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02012959
Other study ID # 156-08-276
Secondary ID 2013-002005-59
Status Terminated
Phase Phase 3
First received
Last updated
Start date September 22, 2015
Est. completion date July 24, 2017

Study information

Verified date July 2018
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial was to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent participants with euvolemic or hypervolemic hyponatremia.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date July 24, 2017
Est. primary completion date July 24, 2017
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion:

- Male and female participants =4 weeks (or =44 weeks adjusted gestational age) to <18 years old

- Participants hospitalized with euvolemic or hypervolemic hyponatremia resistant to initial standard background therapy

- Persistent euvolemic or hypervolemic hyponatremia defined as being documented as <130 milliequivalent (mEq)/L and present for at least 48 hours, evidenced by at least 2 serum sodium assessments (12 hours apart)

- Ability to maintain adequate fluid intake (orally or intravenously)

- Ability to take oral medications

- Ability to comply with all requirements of the trial

- Completion of the trial-specific informed consent/assent as age appropriate

- Ability to commit to remain fully abstinent or practice double-barrier birth control as required by the trial

Exclusion:

- Evidence of hypovolemia or intravascular volume depletion

- Serum sodium <120 mEq/L

- Use of potent cytochrome P450 3A4 (CYP3A4) inhibitors in participants <12 kilogram (kg) or moderate CYP3A4 inhibitors in participants <6 kg

- Lacks free access to water (inability to respond to thirst) or without intensive care unit level fluid monitoring and management

- History or current diagnosis of nephrotic syndrome

- Transient hyponatremia likely to resolve

- Hyperkalemia

- Estimated glomerular filtration rate <30 milliliters/minute/1.73 meters squared

- Acute kidney injury

- Severe or acute neurological symptoms requiring other intervention

- Prior treatment for hyponatremia with hypertonic saline within 8 hours of qualifying serum sodium assessments; urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of qualifying serum sodium assessments; any other treatments for the purpose of increasing serum sodium concurrent with dosing of trial medication

- Anuria or urinary outflow obstruction, unless participant is/can be catheterized

- History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives

- Psychogenic polydipsia

- Uncontrolled diabetes mellitus (defined as fasting glucose >300 milligrams/deciliter)

- Screening liver function values >3 times the upper limit of normal

- Participants who have cirrhosis and meet any of the following conditions: a major GI bleed within the past 6 months, evidence of active bleeding, platelet count <50,000/microliter, or use of concomitant medications known to increase bleeding risk

- Hyponatremia due to the result of any medication that can safely be withdrawn or that is most appropriately corrected by alternative therapies

- History of drug or medication abuse within 3 months prior to screening or current alcohol abuse

- Participants who require suspension formulation and have a Hereditary Fructose Intolerance

- Has hyponatremia that is more appropriately corrected by alternative therapies

- Is pregnant or currently breastfeeding

- Has any medical condition that could interfere with evaluation of trial objectives or participant safety

- Has participated in another investigational drug trial in the last 30 days

- Weighs <3 kg

- Unable to swallow tablets, if suspension unavailable

- Is deemed unsuitable for trial participation in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tolvaptan


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc. Syneos Health

Countries where clinical trial is conducted

United States,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change In Serum Sodium Concentration For Responders Change in serum sodium concentration (mEq/L) for responders from Day 2 (or Day 2a) at the end of Treatment Phase A (where all participants received tolvaptan) to the end of Treatment Phase B for the Early compared to Late Withdrawal groups is reported. Once a participant was randomized to Treatment Phase B, any additional therapies for the purpose of raising serum sodium, including fluid restriction, were considered rescue therapy. Upon receipt of rescue therapy, a participant's endpoint data was collected and then censored from the efficacy analysis thereafter, unless specified. Day 2/2a, Day 4
Secondary Change In Serum Sodium Concentration During Treatment Phase A Change in serum sodium concentration (mEq/L) from baseline to the end of Day 2 (or 2a) during Treatment Phase A for all participants (responders and non-responders) is reported. Baseline, Day 2/2a
Secondary Fluid Balance (Intake Minus Output) During Treatment Phase A Every 6 hours and for the 24-hour daily interval on Days 1 and 2 during Treatment Phase A, fluid balance (milliliters [mL]) was determined by fluid intake (oral and intravenous) minus urine output. Improved fluid balance would be indicated through the induction of increased urine volume. Fluid balance was monitored per institutional guidelines. Every 6 hours on Days 1 and 2
See also
  Status Clinical Trial Phase
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Recruiting NCT04561531 - Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia. N/A
Recruiting NCT02936167 - Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children N/A
Completed NCT00621348 - Maintenance Intravenous Fluids in Children Phase 3
Terminated NCT03703713 - Colloid Osmotic Pressure and Osmolality in Hyponatremia
Completed NCT02926989 - Intravenous Fluids in Hospitalised Children Phase 4
Terminated NCT02959411 - Tolvaptan for Advanced or Refractory Heart Failure Phase 4
Completed NCT02573077 - An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Withdrawn NCT02667977 - Reexamining Hypotonic Intravenous Fluid Use N/A
Terminated NCT01708811 - Hyponatremia and Myometrium Contractility. An Invitro Study N/A
Completed NCT01456533 - Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients N/A
Withdrawn NCT01326429 - Frequency and Origin of Dysnatremias in the Emergency Department N/A
Terminated NCT01227512 - Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia Phase 3
Recruiting NCT06013800 - Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
Terminated NCT04020926 - Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function
Withdrawn NCT02442674 - A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia Phase 3
Completed NCT02545101 - An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH N/A
Terminated NCT02215148 - Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients N/A
Recruiting NCT01748331 - The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia N/A
Not yet recruiting NCT01716611 - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Phase 4